ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1839

Transcriptional Profiling of Whole Blood and Kidney Biopsy Samples from Lupus Nephritis and IgA Nephropathy Patients Suggests Different Disease Pathways

Christopher Sisk1, Loqmane Seridi2, Alan Perlman3, Matthew Loza2, Sheng Gao2, Thomas Parker4, Daniel Levine4, Thangamani Muthukumar5, Yonatan Bardash6, Benjamin Horowitz7, Surya Seshan5 and James Chevalier3, 1Johnson & Johnson, San Diego, CA, USA, San Diego, CA, CA, 2Johnson & Johnson, Spring House, PA, 3The Rogosin Institute, New York, NY, 4The Rogosin Institute, Weill Cornell Medical College, New York, NY, 5Weill Cornell Medical College, New York, NY, 6Hackensack Meridian Health, Hackensack, NJ, 7Columbia University Medical Center, New York, NY

Meeting: ACR Convergence 2025

Keywords: Biomarkers, genomics, Nephritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 28, 2025

Title: (1830–1854) Systemic Lupus Erythematosus – Etiology and Pathogenesis Poster

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Lupus nephritis (LN) is a severe complication of systemic lupus erythematosus (SLE), associated with significant morbidity and mortality. IgA nephropathy (IgAN) is the most common form of primary glomerulonephritis worldwide, characterized by IgA deposition in the glomeruli and subsequent renal damage. Although LN and IgAN share some clinical and immunological similarities, their underlying pathogenic pathways are likely distinct, necessitating further research into their molecular profiles. While the transcriptomic profiles of whole blood samples from SLE patients have been investigated in different cohorts and pointed to the dysregulations of key immune pathways, the differences have not been closely examined in the kidney for LN and IgAN. This study evaluated and compared the transcriptomic profiles of whole blood and kidney biopsy samples from the LN and IgAN patients, as well as the matching healthy controls.

Methods: Samples from 52 patients (34 with LN and 18 with IgAN) were included in this study. Whole blood samples (33 LN and 18 IgAN) were collected in PAXGene tubes. Kidney biopsy samples (24 LN and 16 IgAN) were collected following standard clinical practice, with residual samples preserved for transcriptomic analysis. Healthy control samples including whole blood (n=30) and kidney tissue (n=7) were obtained independently. RNA was extracted from whole blood and kidney samples and used for standard RNA sequencing analysis. In this analysis, statistical significance for differentially expressed genes (DEGs) was defined as a fold change > 2 and FDR < 0.05. Interferon (IFN) gene signature enrichment was quantified using gene set variation analysis (GSVA).

Results: In comparison to healthy controls, there were 2151 differentially expressed genes (DEGs) identified in whole blood of LN patients and 200 DEGs in IgAN patients, respectively. The LN vs IgAN comparison revealed 1054 DEGs. LN DEGs were enriched in Reactome pathways related to “innate immune” and “neutrophil activation”, while IgAN DEGs were enriched in “B cell” and “Fc receptor signaling” pathways. Both LN and IgAN kidney samples exhibited over 3000 DEGs compared to controls and shared similar enriched pathways, with IFN pathway further enriched in LN. The kidney IFN gene signature score correlated with serum creatinine levels and eGFR in both diseases.

Conclusion: Transcriptomic analysis highlighted similar and distinct dysregulated pathways in LN and IgAN whole blood and kidney. Greater differences were observed in whole blood transcriptomics, indicating a greater extent of systemic immunological dysregulation between LN and IgAN. Renal IFN pathway activation was prominent in LN and correlated with the severity of kidney dysfunction in both diseases.


Disclosures: C. Sisk: Johnson & Johnson, 3, 11; L. Seridi: Johnson & Johnson, 3, 11; A. Perlman: Travere, 1; M. Loza: Johnson & Johnson, 3, 11; S. Gao: Johnson & Johnson, 3, 11; T. Parker: None; D. Levine: None; T. Muthukumar: None; Y. Bardash: None; B. Horowitz: None; S. Seshan: None; J. Chevalier: None.

To cite this abstract in AMA style:

Sisk C, Seridi L, Perlman A, Loza M, Gao S, Parker T, Levine D, Muthukumar T, Bardash Y, Horowitz B, Seshan S, Chevalier J. Transcriptional Profiling of Whole Blood and Kidney Biopsy Samples from Lupus Nephritis and IgA Nephropathy Patients Suggests Different Disease Pathways [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/transcriptional-profiling-of-whole-blood-and-kidney-biopsy-samples-from-lupus-nephritis-and-iga-nephropathy-patients-suggests-different-disease-pathways/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/transcriptional-profiling-of-whole-blood-and-kidney-biopsy-samples-from-lupus-nephritis-and-iga-nephropathy-patients-suggests-different-disease-pathways/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology